Causes of death in the era of highly active antiretroviral therapy: A retrospective analysis of a hybrid hematology-oncology and HIV practice and the Seattle/King county adult/adolescent spectrum of HIV-related diseases project

American Journal of the Medical Sciences

Volumn 336, Issue 3, 2008, Pages 217-223

  Uhlenkott, Matthew C ^a   Buskin, Susan E ^b,c   Kahle, Erin M ^b   Barash, Elizabeth ^b   Aboulafia, David M ^a,d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Antiretroviral; Causes of death; HAART; HIV AIDS; Mortality

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; FEMALE; HEAD AND NECK CANCER; HERPES; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPLASMOSIS; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE FUNCTION TEST; ISOSPORIASIS; KAPOSI SARCOMA; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER FAILURE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; NEOPLASM; NONHODGKIN LYMPHOMA; PANCREATITIS; PENIS CANCER; PNEUMONIA; RETROSPECTIVE STUDY; SEPSIS; SUICIDE; THROMBOSIS; TOXOPLASMOSIS; VIRUS LOAD; WASTING SYNDROME; ADDICTION; MIDDLE AGED; UNITED STATES;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BACTERIAL INFECTIONS; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV WASTING SYNDROME; HUMANS; LIVER FAILURE; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS; VIRAL LOAD; WASHINGTON;

EID: 55249103835     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31815d4408     Document Type: Article

References (32)

1. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005;34:121-30.
2. Sterne J, Hernan M, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005;366: 378-84.
3. Walensky R, Paltiel A, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006;194:11-9.
4. van Sighem A, Danner S, Ghani A, et al. Mortality in patients with successful initial response to highly active an-tiretroviral therapy is still higher than in non-HIV-infected individuals. J Acquir Immune Defic Syndr 2005;40:212-18.
5. Sackoff J, Hanna D, Pfeiffer M, et al. Causes of death among persons with AIDS in the era of highly active antiret-roviral therapy: New York City. Ann Intern Med 2006;145: 397-406.
6. Crum N, Riffenburgh R, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of pre-, early, and late HAART (highly active antiretroviral therapy) era. J Aquir Immune Defic Syndr 2006;40:194-200.
7. Palella F, Baker R, Moorman A, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Aquir Immune Defic Syndr 2006;43:27-34.
8. Sabin C, Smith C, Youle M, et al. Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS 2006;20:67-71.
9. Krentz H, Kliewer G, Gill M. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005;6:99- 106.
10. Ives N, Gazzard B, Easterbrook P. The changing pattern of AIDS-defining illnesses with the introduction of highly antiretroviral therapy (HAART) in a London clinic. J Infect 2001;42:134-39.
11. Bonnet F, Lewden C, May T, et al. Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. Scand J Infect Dis 2005;37:482-87.
12. Paterson D, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
13. Kohli R, Lo Y, Howard A, et al. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis 2005;41: 864-72.
14. Gross R, Yip B, Lo Re V, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis 2006;194:1108-04.
15. Lloyd-Smith E, Brodkin E, Wood E, et al. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. AIDS 2006;20: 445-50.
16. Lucas G, Griswold M, Gebo K, et al. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol 2006; 163:412-20.
17. Lumbreras B, Jarrin I, Amo J, et al. Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART. AIDS 2006;20:111-16.
18. Yeung H, Krentz H, Gill M, et al. Neuropsychiatric disorders in HIV infection: impact of diagnosis on economic costs of care. AIDS 2006;20:2005-09.
19. Bouhnik A, Preau M, Vincent E, et al. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Anitvir Ther 2005;10: 53-61.
20. Komiti A, Judd F, Grech P, et al. Suicidal behavior in people with HIV/AIDS in review. Aust NZ J Psychiatry 2001; 35:747-57.
21. Wood E, Hogg R, Yip B, et al. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts ≤200 cells//μL. AIDS 2006;20:1117-23.
22. Hessol N, Kalinowski A, Benning L, et al. Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. CID 2007;44:287- 94.
23. Kushel M, Colfax G, Ragland K, et al. Case management is associated with improved antiretroviral adherence and CD4+ cell counts in homeless and marginally housed individuals with HIV infection. Clin Infect Dis 2006;43:234-42.
24. CASCADE Collaboration. Effective therapy has altered the spectrum of cause-specific mortality following HIV serocon-version. AIDS 2006;20:741-49.
25. Farizo K, Buehler J, Chamberland M, et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA 1992;267:1798-805.
26. Barash E, Kahle E, Buskin S. Summary results from the Adult and Adolescent Spectrum of HIV Disease Project. HIV/ AIDS Epidemiology Report 2nd Half. 2005;17-23. Available at: http://www.metrokc.gov/health/apu/epi/2nd-half- 2005. Accessed on February 20, 2007.
27. Centers for Disease Control, December 18, 1992. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1-19.
28. Semela D, Glatz M, Hunziker D, et al. Causes of death and autopsy findings in patients of the Swiss HIV Cohort Study. Schweiz Med Wochesnschr 2000;130:1726-33.
29. Brousseau K. Psychological aspects of HIV treatment. JAMA 2007;297:157-58.
30. Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005;104:1505-11.
31. Bini E, Park J, Francoi F, et al. Use of flexible sigmoidos-copy to screen for colorectal cancer in HIV-infected patients 50 years of age and older. Arch Intern Med 2006;166:1626- 31.
32. Pantanowitz L, Schlect HP, Dezube BJ. The growing problem on non-AIDS defining malignancies in HIV. Curr Opin Oncol 2006;18:469-78.